Petros Pharmaceuticals, Inc. (PTPI)
USD 0.25
(-7.78%)
USD 0.25
(-7.78%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.19 Million USD | -75.47% |
| 2022 | 3.7 Million USD | -40.39% |
| 2021 | 6.21 Million USD | 12.67% |
| 2020 | 5.51 Million USD | -32.36% |
| 2019 | 8.15 Million USD | 128.27% |
| 2018 | 3.57 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.05 Million USD | 302.33% |
| 2024 Q2 | 374.52 Thousand USD | 3.35% |
| 2023 Q2 | 1.48 Million USD | -24.76% |
| 2023 Q3 | 1.26 Million USD | -14.46% |
| 2023 FY | 908.2 Thousand USD | -75.47% |
| 2023 Q4 | -522.39 Thousand USD | -141.26% |
| 2023 Q1 | 1.96 Million USD | 2463.58% |
| 2022 FY | 3.7 Million USD | -40.39% |
| 2022 Q4 | -83.23 Thousand USD | 95.23% |
| 2022 Q3 | -1.74 Million USD | -149.31% |
| 2022 Q2 | 3.53 Million USD | 77.5% |
| 2022 Q1 | 1.99 Million USD | 279.39% |
| 2021 FY | 6.21 Million USD | 12.67% |
| 2021 Q4 | -1.11 Million USD | -160.84% |
| 2021 Q3 | 1.82 Million USD | -11.55% |
| 2021 Q2 | 2.06 Million USD | -39.85% |
| 2021 Q1 | 3.43 Million USD | 188.91% |
| 2020 FY | 5.51 Million USD | -32.36% |
| 2020 Q4 | 1.18 Million USD | -52.15% |
| 2020 Q3 | 2.48 Million USD | 197.58% |
| 2020 Q2 | 834.33 Thousand USD | -17.22% |
| 2020 Q1 | 1 Million USD | 262.91% |
| 2019 Q1 | 3.82 Million USD | 0.0% |
| 2019 Q4 | -618.66 Thousand USD | -131.72% |
| 2019 FY | 8.15 Million USD | 128.27% |
| 2019 Q3 | 1.95 Million USD | -34.89% |
| 2019 Q2 | 2.99 Million USD | -21.66% |
| 2018 FY | 3.57 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 73.06 Million USD | 94.264% |
| Theratechnologies Inc. | 62.12 Million USD | 93.254% |
| Safety Shot Inc | -74.45 Thousand USD | 5728.978% |
| Cosmos Health Inc. | 4.34 Million USD | 3.642% |
| Cronos Group Inc. | 6.99 Million USD | 40.048% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.05% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1483.224% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 98.647% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 58.412% |
| ProPhase Labs, Inc. | 16.23 Million USD | 74.191% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 11.672% |
| Dynavax Technologies Corporation | 182.11 Million USD | 97.699% |
| Radius Health, Inc. | 307.71 Million USD | 98.638% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -656.568% |
| Alvotech | -69.42 Million USD | 106.037% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 49.741% |
| Alpha Teknova, Inc. | 10.29 Million USD | 59.293% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 99.027% |
| SCYNEXIS, Inc. | 124.51 Million USD | 96.634% |
| Harrow Health, Inc. | 90.55 Million USD | 95.372% |
| Biofrontera Inc. | 16.62 Million USD | 74.793% |
| DURECT Corporation | 6.83 Million USD | 38.645% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.2% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 98.627% |
| OptiNose, Inc. | 62.35 Million USD | 93.278% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -37.228% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 85.913% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 87.484% |
| SIGA Technologies, Inc. | 122.09 Million USD | 96.567% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 89.985% |
| Shineco, Inc. | 882.16 Thousand USD | -375.099% |
| Phibro Animal Health Corporation | 312.48 Million USD | 98.659% |
| Procaps Group S.A. | 239.56 Million USD | 98.251% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -221.902% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 662.129% |
| Viatris Inc. | 6.43 Billion USD | 99.935% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | 49.741% |
| Rockwell Medical, Inc. | 8.7 Million USD | 51.848% |
| Incannex Healthcare Limited | 12 Thousand USD | -34826.4% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 92.322% |
| Tilray Brands, Inc. | 223.35 Million USD | 98.124% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 98.715% |
| PetIQ, Inc. | 252.74 Million USD | 98.342% |
| Silver Spike Investment Corp. | 8.1 Million USD | 48.274% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.773% |
| Journey Medical Corporation | 52.52 Million USD | 92.02% |
| Alimera Sciences, Inc. | 61.17 Million USD | 93.148% |
| Assertio Holdings, Inc. | 125.04 Million USD | 96.648% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 61635.281% |
| Embecta Corp. | 749.9 Million USD | 99.441% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 273.895% |
| Procaps Group, S.A. | 239.56 Million USD | 98.251% |
| PainReform Ltd. | -15 Thousand USD | 28041.12% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 84.544% |
| Hempacco Co., Inc. | -1.21 Million USD | 444.716% |
| Talphera, Inc. | -4.89 Million USD | 185.621% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 99.145% |
| Alvotech | -69.42 Million USD | 106.037% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 99.409% |
| Kamada Ltd. | 52.59 Million USD | 92.031% |
| Indivior PLC | 907 Million USD | 99.538% |
| Currenc Group, Inc. | 17.35 Million USD | 75.852% |
| Evoke Pharma, Inc. | 4.97 Million USD | 15.819% |
| Flora Growth Corp. | 17.73 Million USD | 76.372% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 273.895% |
| Evolus, Inc. | 140.52 Million USD | 97.018% |
| HUTCHMED (China) Limited | 453.55 Million USD | 99.076% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 98.782% |
| Akanda Corp. | 111.44 Thousand USD | -3660.615% |